Premium
Improved remission rates and remission duration in young women with metastatic breast cancer following combined oophorectomy and chemotherapy. A study by cancer and leukemia group B
Author(s) -
Falkson Geoffrey,
Falkson H. C.,
Glidewell O.,
Weinberg V.,
Leone L.,
Holland James F.
Publication year - 1979
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197906)43:6<2215::aid-cncr2820430609>3.0.co;2-3
Subject(s) - medicine , oophorectomy , cyclophosphamide , vincristine , metastatic breast cancer , chemotherapy , breast cancer , cancer , prednisone , surgery , phases of clinical research , gynecology , hysterectomy
One hundred fifty‐seven premenopausal women with metastatic breast cancer were prospectively randomized to treatment consisting of oophorectomy + vincristine, prednisone, cyclophosphamide, methotrexate, 5‐fluorouracil (VPCMF) (Reg. I) or oophorectomy + cyclophosphamide (Reg. II) or oophorectomy followed by an observation period (Phase 1), followed by VPCMF (Phase 2) (Reg. III). Complete plus partial response rates were 72% on Reg. I, 65% on Reg. II, 18% on Reg. III, Phase 1 and 50% on Reg. III, Phase 2. Median duration of response for Reg. I was 17 months, for Reg. II 16 months, and for Phase 1 and Phase 2 of Reg. III, respectively, 5 months and 8 months. The response rate for patients treated with oophorectomy plus chemotherapy is significantly higher than the response rate achieved with oophorectomy alone as first treatment following the appearance of metastases in premenopausal women.